막신증 시장 동향은 기술 발전과 연구 증가로 인한 연구 증가를 나타냅니다. 여러 알킬화제가 막신증 치료제로 출시되고 있습니다. 또한, 면역억제제는 막신증 예방에 활용되고 있습니다.
또한, 승인된 알킬화제의 가용성 증가, 시장 내 막신증 환자 수 증가, 연구 개발 증가로 인해 막신증 치료가 증가하고 있으며, 이는 막신증 시장 규모를 증가시키고 있습니다.
이 시장은 이 분야의 발전으로 인해 북미의 의약품 수요가 증가하고 있으며, Novartis AG, SynAct Pharma, Roxane Laboratories, Inc. 등 주요 경쟁업체들이 활발히 활동하고 있어 향후 시장이 성장할 것으로 예상됩니다.
막신증 시장의 성장을 가속하는 몇 가지 요인이 있는데, 그 중 하나는 현재 막신증 치료법을 개발하고 있는 주요 기업들의 연구개발이 활발해지고 있다는 점입니다. 각 업체들은 치료 목적으로 다양한 신제품을 개발하고 있습니다. 일부 승인은 시장 성장을 가속하고 있습니다.
예를 들어, SynAct Pharma AB의 성명에 따르면 2022년 8월 16일, AP1189의 화학 구조 이름인 Resomelagon이 국제 비독점 이름(INN) 제안 목록 127에 추가되었으며, AP1189의 구조는(2E)-2-(2E)-3-(1-(2-(2-) nitrophenyl) -1H-pyrrol-2-yl) prop-2-en-1-ylidenehydrazine-1-carboximidamide라는 특정 계통명을 가지고 있습니다. 이 이름이 WHO의 INN 후보 목록에 포함되면 레소멜라곤으로 알려지게 됩니다.
레조멜라곤은 멜라노코르틴 수용체 작용제로 작용하여 염증 해소를 촉진한다는 사실과 독특한 화학구조를 가진 AP1189의 INN 명칭에 대한 WHO 가이드라인을 준수한다는 점에서 AP1189의 명칭으로 제안되었습니다.
막신증(MN)의 대부분은 사구체 내에서 보체가 현장에서 활성화되어 사구체 세포의 파괴로 인해 발생하지만, 정확한 분자 과정은 아직 밝혀지지 않았습니다. 파이로포토시스(pyroptosis)는 조직 손상을 일으키고, 염증 반응을 유발하고, 세포를 죽이는 프로그램된 세포 사멸의 특정 형태입니다. 그러나 파이로폽토시스가 MN의 발병과 진행에 관여하는지 여부는 불분명하며, MN에서 파이로폽토시스는 포드세포의 손상을 촉진하는 중요한 요인입니다.
보체 자극이 포도세포에 파이로토시스를 유발하고, 시험관 내에서 파이로토시스를 억제하면 보체 유도성 포도세포 분해가 개선된다는 것을 확인하기 위해 연구진은 먼저 MN 환자의 신장에서 파이로토시스가 발생한다는 것을 발견했습니다. 보체 자극에 의해 포도세포의 미토콘드리아 탈분극과 활성산소종(ROS)의 형성도 일어났지만, ROS를 억제하면 파이로폽토시스가 회복되었습니다. 흥미로운 점은 파이로폽토시스를 억제하면 이러한 작용의 일부가 약화되었습니다는 점입니다.
또한, 연구팀은 수동적 헤이만 신염(PHN)이 발생한 쥐의 신장에 파이로폽토시스가 존재하며, PHN에 의한 신장 손상이 파이로폽토시스 억제 분자에 의해 in vivo에서 완화된다는 것을 발견했습니다. 이러한 결과는 미토콘드리아 기능 장애가 MN에서 보체 유도성 포드세포 파괴를 뒷받침하는 중요한 기전이며, 파이로폽토시스가 이 과정에 중요한 역할을 한다는 것을 보여줍니다. 이 결과는 파이로폽토시스가 향후 MN 치료를 위한 완전히 새로운 치료 표적으로 사용될 가능성에 새로운 빛을 비춥니다.
면역억제제의 가장 중요한 부작용은 감염 가능성이 높아지는 것입니다. 기타 덜 심각한 부작용으로는 구토, 메스꺼움, 과도한 발모, 손 떨림 등이 있습니다. 일반적으로 이러한 부작용은 신체가 면역 억제제에 익숙해지면 사라집니다.
특히 쇠약감과 피로감이 심하고, 체온이 100도를 넘고, 떨림이 있고, 소변을 자주 보고, 소변을 보려고 할 때 불이 나고, 감기에 걸리고, 기침을 하는 등의 부작용은 즉각적인 조치가 필요합니다. 이러한 부작용은 시장 성장을 억제할 수 있습니다.
The membranous nephropathy market trends show rising research owing to the rising technological advancements and research studies. Several alkylating agents are being launched for the treatment of membranous nephropathy. Immunosuppressants are also utilized for prevention of membranous nephropathy.
Furthermore, rising treatment for membranous nephropathy due to the rising availability of approved alkylating agents and increase in the number of membranous nephropathy cases in the market, and an increase in the research and development is driving up the membranous nephropathy market size.
The market is experiencing a growth in demand for drugs from North American areas as a result of the rising advancements in this field. With significant competitors like Novartis AG, SynAct Pharma, Roxane Laboratories, Inc, and Genentech Inc. actively operating in the market, the market will grow in upcoming time.
There are several factors driving the growth of the market one of which is rising research and development by the major key companies currently developing therapies for the treatment of membranous nephropathy. Various novel products are being developed by the companies for treatment purpose. Several approvals are taking place which are enhancing the growth of the market.
For instance, on August 16, 2022, Resomelagon, a name for the AP1189 chemical structure, has been added to the list of suggested International Nonproprietary Names (INN) Proposed List 127, according to a statement from SynAct Pharma AB. The structure of AP1189 has the particular systematic name (2E)-2-(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidenehydrazine-1-carboximidamide. If the name is included to the WHO's list of suggested INNs, it will be known as resomelagon.
Resomelagon has been suggested as a name for AP1189 in order to represent the fact that it promotes the resolution of inflammation via functioning as a melanocortin receptor agonist as well as the fact it adheres to WHO guidelines for naming INNs for the unique chemical structures.
Membranous nephropathy (MN) is mostly caused by podocyte destruction, which is mediated by in situ activation of complement in the glomeruli, but the exact molecular process is still unclear. Pyroptosis is a specific form of programmed cell death that can cause tissue damage, trigger inflammatory reactions, and kill off cells. It is unclear, though, whether pyroptosis plays a role in the onset and course of MN. In MN, pyroptosis is a significant factor in the promotion of podocyte damage.
To confirm that complement stimulation caused pyroptosis in podocytes and that suppressing pyroptosis corrected complement-induced podocyte degradation in vitro, researchers first noticed the development of pyroptosis in the MN patient's kidneys. Podocytes' mitochondrial depolarization and formation of reactive oxygen species (ROS) were also generated by complement stimulation, and their pyroptosis was restored by inhibiting ROS. It's interesting to note that suppressing pyroptosis attenuated some of these effects.
In addition, they discovered that pyroptosis was present in the kidneys of rats with passive Heymann nephritis (PHN), and that PHN-induced kidney damage was alleviated in vivo by molecules that inhibit pyroptosis. These results show that mitochondrial dysfunction is a key mechanism underpinning complement-induced podocyte destruction in MN and that pyroptosis plays a significant role in this process. It sheds new light on the possibility that pyroptosis could be used as a brand-new target for therapy for MN therapy in the future.
A greater likelihood of infection is the most important adverse effect of immunosuppressive medications. Other, less severe adverse effects may include vomiting, nausea, excessive hair growth, and trembling in the hands. Usually, these adverse effects go away when the body becomes used to the immunosuppressant medications.
The following side symptoms require quick attention: feeling especially weak or weary, temperature over 100 degrees or shivers, frequently peeing or burning while trying to pass pee, persistent cold, or cough. These side effects may restrain the growth of market.
The global membranous nephropathy market is segmented based on type, drugs, route of administration and distribution channel.
The immunosuppressive agents category from drugs held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of membranous nephropathy worldwide. Adults with primary membranous nephropathy frequently develop nephrotic syndrome. Without therapy, one-third of patients would have persistent proteinuria and about 30% of patients will undergo spontaneous remission. Within ten years, one-third of patients advance to end-stage kidney disease (ESKD).
Due to the increased risk of developing ESKD, immunosuppressive therapy is advised for patients with serious nephrotic syndrome at present and for those whose proteinuria does not improve with supportive therapy. Different immunosuppressive regimens' efficacy and toxicity are unknown. Inducing remission and lowering the number of patients who proceed towards ESKD, immunosuppressive medication likely outperforms non-immunosuppressive therapy. These advantages must be weighed against the negative effects of immunosuppressive medications, though.
Due to the rising need for membranous nephropathy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for drugs for membranous nephropathy.
Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of infectious disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of membranous nephropathy market share of this region.
It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various drugs such as alkylating agents for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.
The major global players in the membranous nephropathy market include F. Hoffman La Roche, SynAct Pharma, Roxane Laboratories, Inc, Dr. Reddy's Laboratories Ltd., Genentech, Inc., Novartis AG, Anant Pharmaceuticals Pvt. Ltd, Merck KGaA, Panacea Biotec among others.
Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide membranous nephropathy market. The growth of the global membranous nephropathy market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.
The global membranous nephropathy market is going to see moderate growth in upcoming years owing to rising usage of immunosuppressents for membranous nephropathy. Several researches are taking place worldwide for alkylating agents development. Numerous advances are taking place leading to the growth of market such as novel alkylating agents. According to DMI the membranous nephropathy market will see a decent growth with several novel therapies in the market.
The global membranous nephropathy market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE